OncoMatch/Endometrial / Uterine Cancer/POLE (ultramutated)
Endometrial / Uterine CancerPOLE (ultramutated) Clinical Trials
POLE exonuclease domain mutations define the ultramutated subgroup of endometrial cancer (~10%) with the highest tumor mutational burden of any cancer type, conferring exceptional sensitivity to PD-1 checkpoint inhibition. Pembrolizumab and nivolumab have demonstrated high response rates in POLE-mutant endometrial cancer. Trials investigate whether POLE-mutant tumors can be cured with immunotherapy alone, replacing or de-escalating chemotherapy, and early-stage POLE-mutant disease management.
Top recruiting POLE (ultramutated) Endometrial / Uterine Cancer trials
Ranked by phase and US site count. See all 4 trials matched to your profile →
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification
Fudan University
Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features
Leiden University Medical Center
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Canadian Cancer Trials Group
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Memorial Sloan Kettering Cancer Center
Browse other molecular targets with active Endometrial / Uterine Cancer trials.